Adaptimmune Therapeutics PlcFind Ratings Reports
ADAPTIMMUNE THERAPEUTICS's gross profit margin for the second quarter of its fiscal year 2021 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ADAPTIMMUNE THERAPEUTICS is extremely liquid. Currently, the Quick Ratio is 7.85 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 31.80% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||3.1||0.5|
|Net Income ($mil)||-39.07||-29.88|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||285.37||418.99|
|Total Assets ($mil)||389.79||512.2|
|Total Debt ($mil)||22.65||23.31|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||-1223.55||-5602.59|
|Return on Assets||-38.19||-24.73|
|Return on Equity||-53.56||-31.09|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||156.04||154.61|
|Div / share||0.0||0.0|
|Book value / share||1.78||2.64|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1923946.0||870036.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.06 indicates a discount versus the S&P 500 average of 4.47 and a significant discount versus the subsector average of 10.57. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, ADAPTIMMUNE THERAPEUTICS proves to trade at a discount to investment alternatives.
|ADAP NM||Peers 31.77||ADAP NM||Peers 19.67|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ADAP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ADAP's P/CF is negative making the measure meaningless.
|ADAP NM||Peers 17.35||ADAP NA||Peers 0.35|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ADAP's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ADAP 3.06||Peers 10.57||ADAP 15.18||Peers 237.63|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ADAP is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ADAP is expected to significantly trail its peers on the basis of its earnings growth rate.
|ADAP 136.72||Peers 1703.22||ADAP 179.35||Peers 1943.44|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ADAP is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
ADAP significantly trails its peers on the basis of sales growth.